Xeris Biopharma Holdings, Inc. (XERS) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the XERS SEC filings page.
Xeris Biopharma Holdings, Inc. (XERS) reported $335.4M in revenue over the twelve months to Jun 30, 2026, up 36.3% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue scale has finally crossed into operating profitability, but heavy liabilities and interest still leave little net income.
The shift from a negative operating margin in FY2021 to8.5% in FY2025 occurred alongside a gross margin reaching85.4% , indicating fixed-cost absorption and improving operating leverage rather than growth alone. The business is therefore becoming more efficient at converting sales into operating profit, even though financing costs remain consequential.
Cash generation materially outpaced reported earnings: operating cash flow turned positive at
Equity recovered from
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Xeris Biopharma Holdings, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Xeris Biopharma Holdings, Inc. has an operating margin of 8.5%, meaning the company retains $9 of operating profit per $100 of revenue. This below-average margin results in a low score of 25/100, suggesting thin profitability after operating expenses. This is up from -16.6% the prior year.
Xeris Biopharma Holdings, Inc.'s revenue surged 43.7% year-over-year to $291.8M, reflecting rapid business expansion. This strong growth earns a score of 91/100.
Xeris Biopharma Holdings, Inc. has elevated debt relative to equity (D/E of 16.10), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 14/100, reflecting increased financial risk.
Xeris Biopharma Holdings, Inc.'s current ratio of 2.19 indicates adequate short-term liquidity, earning a score of 64/100. The company can meet its near-term obligations, though with limited headroom.
Not available for Xeris Biopharma Holdings, Inc., and counted as zero in the overall score.
Xeris Biopharma Holdings, Inc. generates a 4.0% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 28/100.
Xeris Biopharma Holdings, Inc. scores 2.03, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($1.9B) relative to total liabilities ($369.8M). This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Xeris Biopharma Holdings, Inc. passes 8 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
Xeris Biopharma Holdings, Inc. reported $554K of net income while generating $28.6M in operating cash flow. The ratio between the two is outside the range this page publishes as a per-dollar figure, so both figures are given instead.
Xeris Biopharma Holdings, Inc. earns $0.86 in operating income for every $1 of interest expense ($24.9M vs $29.1M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Xeris Biopharma Holdings, Inc. generated $92.1M in revenue in Q2 2026. This represents an increase of 28.7% from the same quarter a year earlier. Against the prior quarter it is up 10.8%.
Xeris Biopharma Holdings, Inc.'s EBITDA was $5.5M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 14.3% from the same quarter a year earlier. Against the prior quarter it is down 33.4%.
Xeris Biopharma Holdings, Inc. reported -$31.1M in net income in Q2 2026. This represents a decrease of 1513.1% from the same quarter a year earlier. Against the prior quarter it is down 1492.2%.
Xeris Biopharma Holdings, Inc. earned -$0.18 per diluted share (EPS) in Q2 2026. This represents a decrease of 1700.0% from the same quarter a year earlier. Against the prior quarter it is down 1900.0%.
Cash & Balance Sheet
Xeris Biopharma Holdings, Inc. held $121.7M in cash against $188.8M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Xeris Biopharma Holdings, Inc.'s gross margin was 86.4% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 3.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.9 percentage points.
Xeris Biopharma Holdings, Inc.'s operating margin was 5.6% in Q2 2026, reflecting core business profitability. This is down 0.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.9 percentage points.
Xeris Biopharma Holdings, Inc.'s net profit margin was -33.8% in Q2 2026, showing the share of revenue converted to profit. This is down 31.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 36.5 percentage points.
Not reported for Q2 2026.
Capital Allocation
Xeris Biopharma Holdings, Inc. invested $10.7M in research and development in Q2 2026. This represents an increase of 32.5% from the same quarter a year earlier. Against the prior quarter it is up 21.5%.
Not reported for Q2 2026.
Not reported for Q2 2026.
XERS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $92.1M+28.7% | $83.1M+38.3% | $85.8M+42.8% | $74.4M+37.1% | $71.5M+48.8% | $60.1M+47.9% | $60.1M+35.4% | $54.3M+12.3% |
| Cost of Revenue | $12.5M+5.2% | $10.6M+21.2% | $10.9M+15.5% | $11.0M-19.1% | $11.9M+52.7% | $8.7M+46.2% | $9.5M+25.2% | $13.6M+65.7% |
| Gross Profit | $79.6M+33.4% | $72.6M+41.2% | $74.9M+47.9% | $63.4M+55.8% | $59.6M+48.1% | $51.4M+48.2% | $50.6M+37.5% | $40.7M+1.4% |
| R&D Expenses | $10.7M+32.5% | $8.8M+13.3% | $7.9M+29.3% | $7.5M+27.1% | $8.1M+39.9% | $7.8M-0.9% | $6.1M-4.5% | $5.9M+17.0% |
| SG&A Expenses | $61.0M+37.5% | $53.1M+20.7% | $47.5M+18.3% | $46.5M+3.3% | $44.4M+11.0% | $44.0M+14.7% | $40.1M+6.8% | $45.0M+20.6% |
| Operating Income | $5.2M+15.4% | $7.9M+356.2% | $16.8M+899.0% | $6.7M+152.2% | $4.5M+154.7% | -$3.1M+78.3% | $1.7M+117.1% | -$12.9M-162.4% |
| EBITDA | $5.5M+14.3% | $8.3M+397.4% | $17.1M+758.8% | $7.1M+156.2% | $4.8M+160.8% | -$2.8M+80.1% | $2.0M+121.0% | -$12.6M-178.3% |
| Interest Expense | $6.9M-5.6% | $6.9M-5.8% | $7.2M-7.1% | $7.3M-6.7% | $7.4M-7.6% | $7.3M+3.9% | $7.7M+9.8% | $7.8M+13.7% |
| Income Tax | $0 | $0 | $0 | $0+100.0% | $0-100.0% | $0-100.0% | $0+100.0% | -$3.3M-883.4% |
| Net Income | -$31.1M-1513.1% | $2.2M+124.2% | $11.1M+316.7% | $621K+103.9% | -$1.9M+87.2% | -$9.2M+51.4% | -$5.1M+61.8% | -$15.7M-29.1% |
| EPS (Basic) | -$0.18-1700.0% | $0.01+116.7% | $0.07+333.3% | $0.00+100.0% | -$0.01+90.0% | -$0.06+57.1% | -$0.03+66.7% | -$0.11-22.2% |
| EPS (Diluted) | -$0.18-1700.0% | $0.01+116.7% | $0.07+333.3% | $0.00+100.0% | -$0.01+90.0% | -$0.06+57.1% | -$0.03+66.7% | -$0.11-22.2% |
| Diluted Shares (Avg) | 173M+8.4% | 178M+16.5% | N/A | 178M+19.2% | 159M+7.5% | 152M+8.5% | N/A | 149M+7.9% |
XERS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $411.9M+23.1% | $392.0M+24.3% | $383.5M+18.7% | $370.2M+15.3% | $334.7M+0.9% | $315.5M-6.3% | $323.1M+0.1% | $321.1M-2.0% |
| Current Assets | $274.8M+48.1% | $251.7M+53.9% | $240.3M+43.3% | $224.0M+37.6% | $185.6M+8.9% | $163.5M-5.6% | $167.7M+7.3% | $162.8M+3.0% |
| Cash & Equivalents | $121.7M+105.4% | $111.8M+91.2% | $111.0M+55.0% | $91.6M+54.6% | $59.3M+2.9% | $58.4M-6.8% | $71.6M+6.2% | $59.2M+28.4% |
| Short-Term Investments | $0 | $0 | $0 | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% | $10.2M-48.7% |
| Inventory | $80.9M+20.3% | $74.2M+40.9% | $68.7M+42.5% | $67.5M+49.5% | $67.3M+56.6% | $52.7M+28.9% | $48.2M+24.0% | $45.1M+18.3% |
| Accounts Receivable | $58.1M+9.5% | $56.3M+21.5% | $51.0M+26.3% | $53.8M+30.7% | $53.0M+25.0% | $46.3M+23.8% | $40.4M+3.1% | $41.1M-10.5% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $22.9M0.0% | $22.9M0.0% | $22.9M0.0% | $22.9M0.0% | $22.9M0.0% | $22.9M0.0% | $22.9M0.0% | $22.9M0.0% |
| Total Liabilities | $421.6M+19.1% | $379.0M+8.1% | $369.8M+4.9% | $371.1M+6.2% | $354.0M+0.8% | $350.6M+1.4% | $352.7M+7.1% | $349.4M+7.9% |
| Current Liabilities | $189.6M+99.2% | $118.6M+24.7% | $109.6M+9.1% | $116.2M+27.7% | $95.2M+26.1% | $95.1M+30.1% | $100.4M+5.5% | $91.0M+4.6% |
| Non-Current Liabilities | $232.1M-10.3% | $260.4M+1.9% | $260.3M+3.2% | $254.9M-1.4% | $258.8M-6.1% | $255.5M-6.3% | $252.2M+7.7% | $258.4M+9.1% |
| Long-Term Debt | $188.8M-13.6% | $221.2M+1.6% | $220.3M+1.5% | $219.5M+1.5% | $218.6M-5.1% | $217.8M-5.2% | $217.0M+13.7% | $216.2M+13.6% |
| Total Equity | -$9.7M+49.6% | $13.0M+137.0% | $13.7M+146.2% | -$861K+97.0% | -$19.3M-0.1% | -$35.1M-282.7% | -$29.6M-336.7% | -$28.3M-832.8% |
| Retained Earnings | -$700.2M-2.5% | -$669.1M+1.8% | -$671.3M+0.1% | -$682.4M-2.3% | -$683.0M-4.9% | -$681.1M-7.1% | -$671.9M-8.9% | -$666.7M-10.5% |
XERS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $8.3M+4440.1% | $9.9M+198.4% | $20.0M+914.8% | $18.4M+321.9% | $182K+101.8% | -$10.0M+50.6% | $2.0M-73.6% | -$8.3M+43.2% |
| Depreciation & Amortization | $323K-0.6% | $337K+7.0% | $335K+7.0% | $338K+10.1% | $325K+15.7% | $315K-3.4% | $313K-9.5% | $307K-21.5% |
| Stock-Based Compensation | $11.1M+121.0% | $4.1M-6.8% | N/A | $7.6M+12.9% | $5.0M+18.3% | $4.4M+17.9% | N/A | $6.8M+175.5% |
| Investing Cash Flow | -$209K+25.1% | -$325K-2400.0% | -$333K-103.3% | -$71K-100.7% | -$279K-106.1% | -$13K+99.9% | $10.0M-32.6% | $9.9M-32.4% |
| Financing Cash Flow | $1.9M+106.3% | -$8.8M-181.7% | -$266K-166.8% | $13.8M+16786.7% | $942K+42.9% | -$3.1M-108.9% | $398K+132.3% | -$83K-15.3% |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
XERS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 86.4%+3.0pp | 87.3%+1.8pp | 87.2%+3.0pp | 85.2%+10.3pp | 83.4%-0.4pp | 85.5%+0.2pp | 84.2%+1.3pp | 75.0%-8.1pp |
| Operating Margin | 5.6%-0.7pp | 9.5%+14.7pp | 19.6%+16.8pp | 9.0%+32.8pp | 6.3%+23.3pp | -5.1%+29.9pp | 2.8%+25.0pp | -23.8%-13.6pp |
| Net Margin | -33.8%-31.1pp | 2.7%+18.0pp | 12.9%+21.4pp | 0.8%+29.8pp | -2.7%+28.5pp | -15.3%+31.4pp | -8.5%+21.6pp | -29.0%-3.8pp |
| Return on Equity | N/A | 17.2% | 81.0% | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -7.5%-7.0pp | 0.6%+3.5pp | 2.9%+4.5pp | 0.2%+5.1pp | -0.6%+3.9pp | -2.9%+2.7pp | -1.6%+2.6pp | -4.9%-1.2pp |
| Current Ratio | 1.45-0.5x | 2.12+0.4x | 2.19+0.5x | 1.93+0.1x | 1.95-0.3x | 1.72-0.7x | 1.670.0x | 1.790.0x |
| Debt-to-Equity | N/A | 17.00 | 16.10 | N/A | N/A | N/A | N/A | N/A |
| Asset Turnover | 0.220.0x | 0.210.0x | 0.220.0x | 0.200.0x | 0.21+0.1x | 0.19+0.1x | 0.190.0x | 0.170.0x |
Not reported in any period shown, so not listed: FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Xeris Biopharma Holdings, Inc. XERS | FY2025 | $291.8M | $554K | 0.2% | $1.9B | 37/100 |
| Amylyx Pharmaceuticals, Inc. AMLX | FY2025 | $0 | -$144.7M | N/A | $3.5B | — |
| Intellia Therapeutics, Inc NTLA | FY2025 | $67.7M | -$412.7M | N/A | $1.8B | 65/100 |
| Tourmaline Bio, Inc. TRML | FY2024 | N/A | -$73.2M | N/A | $1.2B | — |
| Dianthus Therapeutics, Inc. DNTH | FY2025 | $2.0M | -$162.3M | N/A | $4.6B | 55/100 |
| Precigen, Inc. PGEN | FY2025 | $9.7M | -$250.6M | N/A | $2.8B | 49/100 |
Where Xeris Biopharma Holdings, Inc. Ranks
Frequently Asked Questions
What is Xeris Biopharma Holdings, Inc.'s annual revenue?
Xeris Biopharma Holdings, Inc. (XERS) reported $291.8M in total revenue for fiscal year 2025. This represents a 43.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Xeris Biopharma Holdings, Inc.'s revenue growing?
Xeris Biopharma Holdings, Inc. (XERS) revenue grew by 43.7% year-over-year, from $203.1M to $291.8M in fiscal year 2025.
Is Xeris Biopharma Holdings, Inc. profitable?
Yes, Xeris Biopharma Holdings, Inc. (XERS) reported a net income of $554K in fiscal year 2025, with a net profit margin of 0.2%.
What is Xeris Biopharma Holdings, Inc.'s EBITDA?
Xeris Biopharma Holdings, Inc. (XERS) had EBITDA of $26.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Xeris Biopharma Holdings, Inc. have?
As of fiscal year 2025, Xeris Biopharma Holdings, Inc. (XERS) had $111.0M in cash and equivalents against $220.3M in long-term debt.
What is Xeris Biopharma Holdings, Inc.'s gross margin?
Xeris Biopharma Holdings, Inc. (XERS) had a gross margin of 85.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Xeris Biopharma Holdings, Inc.'s operating margin?
Xeris Biopharma Holdings, Inc. (XERS) had an operating margin of 8.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Xeris Biopharma Holdings, Inc.'s net profit margin?
Xeris Biopharma Holdings, Inc. (XERS) had a net profit margin of 0.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Xeris Biopharma Holdings, Inc.'s return on equity (ROE)?
Xeris Biopharma Holdings, Inc. (XERS) has a return on equity of 4.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Xeris Biopharma Holdings, Inc.'s operating cash flow?
Xeris Biopharma Holdings, Inc. (XERS) generated $28.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Xeris Biopharma Holdings, Inc.'s total assets?
Xeris Biopharma Holdings, Inc. (XERS) had $383.5M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Xeris Biopharma Holdings, Inc. spend on research and development?
Xeris Biopharma Holdings, Inc. (XERS) invested $31.2M in research and development during fiscal year 2025.
What is Xeris Biopharma Holdings, Inc.'s current ratio?
Xeris Biopharma Holdings, Inc. (XERS) had a current ratio of 2.19 as of fiscal year 2025, which is generally considered healthy.
What is Xeris Biopharma Holdings, Inc.'s debt-to-equity ratio?
Xeris Biopharma Holdings, Inc. (XERS) had a debt-to-equity ratio of 16.10 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Xeris Biopharma Holdings, Inc.'s return on assets (ROA)?
Xeris Biopharma Holdings, Inc. (XERS) had a return on assets of 0.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Xeris Biopharma Holdings, Inc.'s P/E ratio?
Xeris Biopharma Holdings, Inc. (XERS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $1.9B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Xeris Biopharma Holdings, Inc.'s price-to-sales ratio?
Xeris Biopharma Holdings, Inc. (XERS) trades at 5.7x sales, its market capitalization divided by revenue of $335.4M revenue, trailing 12 months to June 30, 2026. The market capitalization is $1.9B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Xeris Biopharma Holdings, Inc.'s Altman Z-Score?
Xeris Biopharma Holdings, Inc. (XERS) has an Altman Z-Score of 2.03, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Xeris Biopharma Holdings, Inc.'s Piotroski F-Score?
Xeris Biopharma Holdings, Inc. (XERS) has a Piotroski F-Score of 8 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Xeris Biopharma Holdings, Inc.'s earnings high quality?
Xeris Biopharma Holdings, Inc. (XERS) reported $554K of net income while generating $28.6M in operating cash flow. The ratio between the two is outside the range this page publishes as a per-dollar figure, so both figures are given instead. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Xeris Biopharma Holdings, Inc. cover its interest payments?
Xeris Biopharma Holdings, Inc. (XERS) has an interest coverage ratio of 0.86x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Xeris Biopharma Holdings, Inc.?
Xeris Biopharma Holdings, Inc. (XERS) scores 37 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.